Entity Details

Primary name HGNAT_HUMAN
Entity type UniProt
Source Source Link

Details

AccessionQ68CP4
EntryNameHGNAT_HUMAN
FullNameHeparan-alpha-glucosaminide N-acetyltransferase
TaxID9606
Evidenceevidence at protein level
Length663
SequenceStatuscomplete
DateCreated2007-01-23
DateModified2021-06-02

Ontological Relatives

GenesHGSNAT

GO terms

Show/Hide Table
GOName
GO:0005765 lysosomal membrane
GO:0005886 plasma membrane
GO:0006027 glycosaminoglycan catabolic process
GO:0007041 lysosomal transport
GO:0015019 heparan-alpha-glucosaminide N-acetyltransferase activity
GO:0016021 integral component of membrane
GO:0016746 acyltransferase activity
GO:0035579 specific granule membrane
GO:0043312 neutrophil degranulation
GO:0051259 protein complex oligomerization
GO:0070821 tertiary granule membrane

Subcellular Location

Show/Hide Table
Subcellular Location
Lysosome membrane

Domains

Show/Hide Table
DomainNameCategoryType
IPR012429 Heparan-alpha-glucosaminide N-acetyltransferase, catalytic domainDomainDomain
IPR040208 Heparan-alpha-glucosaminide N-acetyltransferaseFamilyFamily

Diseases

Show/Hide Table
Disease IDSourceNameDescription
252930 OMIMMucopolysaccharidosis 3C (MPS3C)A form of mucopolysaccharidosis type 3, an autosomal recessive lysosomal storage disease due to impaired degradation of heparan sulfate. MPS3 is characterized by severe central nervous system degeneration, but only mild somatic disease. Onset of clinical features usually occurs between 2 and 6 years; severe neurologic degeneration occurs in most patients between 6 and 10 years of age, and death occurs typically during the second or third decade of life. The disease is caused by variants affecting the gene represented in this entry.
616544 OMIMRetinitis pigmentosa 73 (RP73)A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. The disease is caused by variants affecting the gene represented in this entry.

Interactions

0 interactions

InteractorPartnerSourcesPublicationsLink